ArticleFrontiers in molecular biosciences2026
Glucosidase GANAB drives colorectal cancer progression through Wnt signaling and is modulated by lncRNA FIRRE.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The goal of this study is to investigate the expression pattern of GANAB in colorectal cancer and the role behind it. Methods: In order to study the expression level of GANAB in the tissue of colorectal cancer, we used quantitative real-time PCR and immunohistochemistry. In the aspect of biological function, we study it through the experimental models. The molecular mechanism is clarified by RNA pull-down and RNA stability assays. Student's t-tests and one-way ANOVA are used for data analysis. Results: Analysis of tissue microarrays and Colorectal cancer (CRC) cell lines revealed elevated GANAB expression in tumors compared to normal counterparts. Increased GANAB levels were linked to enhanced cell migration, invasion, and proliferation, and correlated with metastatic potential and unfavorable patient outcomes. Functional enrichment studies indicated that GANAB-associated genes participate in the Wnt/β-catenin signaling pathway. Immunohistochemistry confirmed positive correlations between GANAB and both c-Myc and β-catenin. The oncogenic function of GANAB was shown to rely on Wnt pathway activation. Additionally, lncRNA FIRRE, known to be oncogenic in CRC, was found to physically interact with GANAB mRNA Conclusion: Our study demonstrates that GANAB exerts oncogenic effects in CRC by binding directly to lncRNA FIRRE, thereby stabilizing GANAB mRNA and activating the Wnt/β-catenin pathway through nuclear accumulation of β-catenin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.